{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:47:31Z","timestamp":1784126851219,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circulating microRNAs (miRNAs) play a role in modulating the prevalence of fibrosis and have been a target of the cardiac anti-fibrotic effect of Carvedilol. However, the impact of miRNAs on the hepatoprotective effect of this non-selective \u03b2-blocker has not been yet elucidated. Hence, the current goal is to evaluate the potential role of circulating miR-200a in the hepatic anti-fibrotic pathway of Carvedilol. Male Wistar rats were randomized into normal, CCl<jats:sub>4<\/jats:sub> (2\u2009ml\/kg, i.p, twice weekly for 8 weeks), and CCl<jats:sub>4<\/jats:sub>\u2009+\u2009Carvedilol (10\u2009mg\/kg, p.o, daily). Carvedilol over-expressed the circulating miR-200a to modulate epithelial mesenchymal transition (EMT) markers (vimentin, E-Cadherin). In turn, Carvedilol increased SMAD7 gene expression and protein content to attenuate the pro-fibrogenic marker transforming growth factor \u03b21 (TGF-\u03b21) and the inflammatory markers (p-38 MAPK and <jats:italic>p<\/jats:italic>-S536-NF-\u03baB p65). The anti-fibrotic potential was reflected on the decreased expression of the mesenchymal product and EMT marker \u03b1-SMA, besides the improved histopathological examination, and the fibrosis scores\/collagen quantification to enhance liver functions (AST, ALT, ALP, and AST\/platelet ratio index; APRI). In conclusion, circulating miR-200a\/SMAD7\/TGF-\u03b21\/EMT\/MAPK axis is crucial in the hepatic anti-fibrotic mechanism of Carvedilol.<\/jats:p>","DOI":"10.1038\/s41598-018-32309-1","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T10:15:30Z","timestamp":1537352130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Anti-fibrotic impact of Carvedilol in a CCl-4 model of liver fibrosis via serum microRNA-200a\/SMAD7 enhancement to bridle TGF-\u03b21\/EMT track"],"prefix":"10.1038","volume":"8","author":[{"given":"Sara A.","family":"El-Wakeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania M.","family":"Rahmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan S.","family":"El-Abhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"32309_CR1","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: Concept to treatment. J Hepatol 62, S15\u2013S24 (2015).","journal-title":"J Hepatol"},{"key":"32309_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11894-009-0080-9","volume":"12","author":"AJ Thompson","year":"2010","unstructured":"Thompson, A. J. & Patel, K. Antifibrotic therapies: will we ever get there? Curr Gastroenterol Rep. 12, 23\u201329 (2010).","journal-title":"Curr Gastroenterol Rep."},{"key":"32309_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/713611034","volume":"33","author":"LW Weber","year":"2003","unstructured":"Weber, L. W., Boll, M. & Stampfl, A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 33, 105\u2013136 (2003).","journal-title":"Crit Rev Toxicol."},{"key":"32309_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2009.11.056","volume":"391","author":"T Ogawa","year":"2010","unstructured":"Ogawa, T. et al. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun. 391, 316\u2013321 (2010).","journal-title":"Biochem Biophys Res Commun."},{"key":"32309_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00441-016-2464-0","volume":"3658","author":"RC Stone","year":"2016","unstructured":"Stone, R. C. et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell and Tissue Research. 3658, 495\u2013506 (2016).","journal-title":"Cell and Tissue Research."},{"issue":"1","key":"32309_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4238\/2014.February.20.2","volume":"13","author":"WR Bi","year":"2014","unstructured":"Bi, W. R., Xu, G. T., Lv, L. X. & Yang, C. Q. The ratio of transforming growth factor-\u03b21\/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis. Genet. Mol. Res. 13(1), 1005\u20131014 (2014).","journal-title":"Genet. Mol. Res."},{"key":"32309_CR7","first-page":"1599","volume":"27","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 27, 1599\u201315605 (2012).","journal-title":"Oncol Rep"},{"key":"32309_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/hepr.12730","volume":"47","author":"Y Murakami","year":"2017","unstructured":"Murakami, Y. & Kawada, N. MicroRNAs in hepatic pathophysiology. Hepatol Res. 47, 60\u201369 (2017).","journal-title":"Hepatol Res."},{"key":"32309_CR9","doi-asserted-by":"publisher","first-page":"F369","DOI":"10.1152\/ajprenal.00268.2011","volume":"302","author":"M Xiong","year":"2011","unstructured":"Xiong, M. et al. The miR-200 family regulates TGF-\u03b21-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 302, F369\u2013379 (2011).","journal-title":"Am J Physiol Renal Physiol."},{"key":"32309_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest. 119, 1420\u20131428 (2009).","journal-title":"J Clin Invest."},{"key":"32309_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1369\/0022155415627681","volume":"64","author":"F Xu","year":"2016","unstructured":"Xu, F., Liu, C., Zhou, D. & Zhang, L. TGF-\u03b2\/SMAD pathway and its regulation in hepatic Fibrosis. J Histochem Cytochem. 64, 157\u2013167 (2016).","journal-title":"J Histochem Cytochem."},{"key":"32309_CR12","first-page":"1366","volume":"6","author":"P Kavsak","year":"2000","unstructured":"Kavsak, P. et al. Smad7 binds to Smurf 2 to form an E3ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell Biochem. 6, 1366\u20131375 (2000).","journal-title":"Mol Cell Biochem."},{"issue":"45","key":"32309_CR13","doi-asserted-by":"publisher","first-page":"32258","DOI":"10.1074\/jbc.274.45.32258","volume":"274","author":"Hong-Jian Zhu","year":"1999","unstructured":"Zhu, H. J. & Sizeland, A. M. Smad7 differentially regulates transforming growth factor b-mediated signaling pathways. J Biol Chem 274 (1999).","journal-title":"Journal of Biological Chemistry"},{"key":"32309_CR14","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.clinre.2015.05.005","volume":"39","author":"D Schuppan","year":"2015","unstructured":"Schuppan, D. Liver fibrosis: Common mechanisms and antifibrotic therapies. Clin Res Hepatol Gastroenterol. 39, S51\u2013S59 (2015).","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"32309_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pharmthera.2009.05.002","volume":"123","author":"KE Porter","year":"2009","unstructured":"Porter, K. E. & Turner, N. A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123, 255\u2013278 (2009).","journal-title":"Pharmacol Ther"},{"key":"32309_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.taap.2012.04.012","volume":"261","author":"N Hamdy","year":"2012","unstructured":"Hamdy, N. & El-Demerdash, E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol. 261, 292\u2013299 (2012).","journal-title":"Toxicol Appl Pharmacol."},{"key":"32309_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/MEG.0b013e3283367a99","volume":"22","author":"D Tripathi","year":"2010","unstructured":"Tripathi, D. & Hayes, P. C. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 22, 905\u2013911 (2010).","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"32309_CR18","doi-asserted-by":"publisher","first-page":"e0148868","DOI":"10.1371\/journal.pone.0148868","volume":"11","author":"Raimundo Fernandes de Ara\u00fajo J\u00fanior","year":"2016","unstructured":"Ara\u00fajo J\u00fanior, R. F. et al. Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol induced liver injury in rats by regulating Kuppfer cells and hepatic stellate cells. PLoS One. 11 (2016).","journal-title":"PLOS ONE"},{"key":"32309_CR19","doi-asserted-by":"publisher","first-page":"e75557","DOI":"10.1371\/journal.pone.0075557","volume":"8","author":"JN Zhu","year":"2013","unstructured":"Zhu, J. N. et al. Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. PLoS One. 8, e75557 (2013).","journal-title":"PLoS One."},{"key":"32309_CR20","first-page":"5813","volume":"21","author":"P Gao","year":"2017","unstructured":"Gao, P., Yang, B., Yu, H. Y., Meng, R. R. & Si, J. Y. Carvedilol alleviates the biliary cirrhosis through inhibiting the endoplasmic reticulum stress. Eur Rev Med Pharmacol Sci. 21, 5813\u20135820 (2017).","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"32309_CR21","first-page":"4612769","volume":"2017","author":"X Tian","year":"2017","unstructured":"Tian, X. et al. Carvedilol attenuates the progression of hepatic fibrosis induced by bile duct ligation. Biomed Res Int. 2017, 4612769 (2017).","journal-title":"Biomed Res Int."},{"key":"32309_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1172\/JCI66028","volume":"123","author":"D Schuppan","year":"2013","unstructured":"Schuppan, D. & Kim, Y. Evolving therapies for liver fibrosis. J Clin Invest. 123, 1887\u20131901 (2013).","journal-title":"J Clin Invest."},{"issue":"9","key":"32309_CR23","doi-asserted-by":"publisher","first-page":"e72928","DOI":"10.1371\/journal.pone.0072928","volume":"8","author":"Barbara Sigala","year":"2013","unstructured":"Sigala, B. et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One. 8 (2013).","journal-title":"PLoS ONE"},{"key":"32309_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.lfs.2017.10.034","volume":"193","author":"N Nuamnaichati","year":"2018","unstructured":"Nuamnaichati, N., Sato, V. H., Moongkarndi, P., Parichatikanond, W. & Mangmool, S. Sustained \u03b2-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation. Life Sci. 193, 257\u2013269 (2018).","journal-title":"Life Sci."},{"key":"32309_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.addr.2017.10.011","volume":"121","author":"CL Wilson","year":"2017","unstructured":"Wilson, C. L., Mann, D. A. & Borthwick, L. A. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev. 121, 124\u2013132 (2017).","journal-title":"Adv Drug Deliv Rev."},{"key":"32309_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11010-013-1895-0","volume":"388","author":"X Sun","year":"2014","unstructured":"Sun, X. et al. Participation of miR-200a in TGF-\u03b21-mediated hepatic stellate cell activation. Mol Cell Biochem. 388, 11\u201323 (2014).","journal-title":"Mol Cell Biochem."},{"key":"32309_CR27","doi-asserted-by":"publisher","first-page":"e16081","DOI":"10.1371\/journal.pone.0016081","volume":"6","author":"Y Murakami","year":"2011","unstructured":"Murakami, Y. et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One. 6, e16081 (2011).","journal-title":"PLoS One."},{"key":"32309_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semnephrol.2012.04.002","volume":"32","author":"HY Lan","year":"2012","unstructured":"Lan, H. Y. & Chung, A. C. TGF-\u03b2\/Smad signaling in kidney disease. Semin Nephrol. 32, 236\u2013243 (2012).","journal-title":"Semin Nephrol."},{"key":"32309_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/db10-0892","volume":"60","author":"B Wang","year":"2011","unstructured":"Wang, B. et al. miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 60, 280\u2013287 (2011).","journal-title":"Diabetes"},{"key":"32309_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopha.2017.07.104","volume":"95","author":"Hao Zhang","year":"2017","unstructured":"Zhang, H., Hu, J. & Liu, L. P. MiR-200a modulates TGF-\u03b21-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs. Biomed Pharmacother. 95 (2017).","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"32309_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/nep.12831","volume":"22","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Pirfenidone suppresses MAPK signaling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. Nephrology (Carlton). 22, 589\u2013597 (2017).","journal-title":"Nephrology (Carlton)."},{"key":"32309_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1159\/000374096","volume":"33","author":"M Pinzani","year":"2015","unstructured":"Pinzani, M. Pathophysiology of Liver Fibrosis. Dig Dis. 33, 492\u2013497 (2015).","journal-title":"Dig Dis."},{"key":"32309_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3892\/br.2016.578","volume":"4","author":"YL Zhao","year":"2016","unstructured":"Zhao, Y. L., Zhu, R. T. & Sun, Y. L. Epithelial-mesenchymal transition in liver fibrosis (Review). Biomedical reports. 4, 269\u2013274 (2016).","journal-title":"Biomedical reports."},{"key":"32309_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/0272-6386(95)90610-X","volume":"26","author":"ED Hay","year":"1995","unstructured":"Hay, E. D. & Zuk, A. Transformations between epithelium and mesenchyme: normal, pathological and experimentally induced. Am J Kidney Dis 26, 678\u2013690 (1995).","journal-title":"Am J Kidney Dis"},{"key":"32309_CR35","first-page":"548","volume":"17","author":"MA Huber","year":"2005","unstructured":"Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Cell Biol 17, 548\u2013558 (2005).","journal-title":"Cell Biol"},{"key":"32309_CR36","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1096\/fj.09-151639","volume":"24","author":"MG Mendez","year":"2010","unstructured":"Mendez, M. G., Kojima, S. & Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 24, 1838\u20131851 (2010).","journal-title":"FASEB J"},{"key":"32309_CR37","doi-asserted-by":"crossref","unstructured":"Lu, Y. et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer. 14 (2014).","DOI":"10.1186\/1471-2407-14-85"},{"key":"32309_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11010-017-2988-y","volume":"431","author":"M Xu","year":"2017","unstructured":"Xu, M. et al. TGF-\u03b21-miR-200a-PTEN induces epithelial-mesenchymal transition and fibrosis of pancreatic stellate cells. Mol Cell Biochem. 431, 161\u2013168 (2017).","journal-title":"Mol Cell Biochem."},{"key":"32309_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000479168","volume":"137","author":"Y Gong","year":"2017","unstructured":"Gong, Y. et al. MicroRNA-200a Inhibits transforming growth factor \u03b21-Induced proximal tubular epithelial-mesenchymal transition by targeting \u03b2-Catenin. Nephron. 137, 237\u2013249 (2017).","journal-title":"Nephron."},{"key":"32309_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.etap.2014.03.011","volume":"37","author":"JQ Ma","year":"2014","unstructured":"Ma, J. Q., Ding, J., Zhang, L. & Liu, C. M. Ursolic acid protects mouse liver against CCl4-induced oxidative stress and inflammation by the MAPK\/NF-\u03baB pathway. Environ Toxicol Pharmacol. 37, 975\u2013983 (2014).","journal-title":"Environ Toxicol Pharmacol."},{"key":"32309_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.intimp.2017.03.029","volume":"47","author":"R Wang","year":"2017","unstructured":"Wang, R., Zhang, H., Wang, Y., Song, F. & Yuan, Y. Inhibitory effects of quercetin on the progression of liver fibrosis through the regulation of NF-\u043aB\/I\u043aB\u03b1, p38 MAPK, and Bcl-2\/Bax signaling. Int Immunopharmacol 47, 126\u2013133 (2017).","journal-title":"Int Immunopharmacol"},{"key":"32309_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/IAI.01412-06","volume":"75","author":"CM Olson","year":"2007","unstructured":"Olson, C. M. et al. p38 Mitogen-activated protein kinase controls NF-\u03baB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen-and stress-activated protein kinase 1 in response to borrelia burgdorferi antigens. Infect Immun 75, 270\u2013277 (2007).","journal-title":"Infect Immun"},{"key":"32309_CR43","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.exphem.2008.03.004","volume":"36","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino, A. et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol. 36, 1035\u20131046 (2008).","journal-title":"Exp Hematol."},{"key":"32309_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.intimp.2015.02.027","volume":"26","author":"DT Wang","year":"2015","unstructured":"Wang, D. T. et al. Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-\u03b2\/Smad and NF-\u03baB signaling pathway in 5\/6 nephrectomized rats. Int Immunopharmacol 26, 4\u201312 (2015).","journal-title":"Int Immunopharmacol"},{"key":"32309_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gut.2010.214650","volume":"59","author":"L Castera","year":"2010","unstructured":"Castera, L. & Pinzani, M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 59, 861\u2013866 (2010).","journal-title":"Gut."},{"key":"32309_CR46","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/aps.2014.41","volume":"35","author":"JP Li","year":"2014","unstructured":"Li, J. P. et al. Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis. Acta Pharmacol Sin. 35, 1031\u20131044 (2014).","journal-title":"Acta Pharmacol Sin."},{"issue":"2","key":"32309_CR47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996).","journal-title":"Hepatology"},{"key":"32309_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.phrs.2008.06.011","volume":"58","author":"J Iredale","year":"1996","unstructured":"Iredale, J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res. 58, 129\u2013136 (1996).","journal-title":"Pharmacol Res."},{"key":"32309_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1172\/JCI1018","volume":"102","author":"JP Iredale","year":"1998","unstructured":"Iredale, J. P. et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 102, 538\u2013549 (1998).","journal-title":"J Clin Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32309-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:47:40Z","timestamp":1671616060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32309-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32309"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32309-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"1 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14327"}}